{
    "nct_id": "NCT04315064",
    "official_title": "Infusion of Panobinostat (MTX110) Into the Fourth Ventricle or Tumor Resection Cavity in Children and Adults with Recurrent Medulloblastoma: a Pilot Study",
    "inclusion_criteria": "* Diagnosis: Patients with histologically verified medulloblastoma with recurrence or progression involving anywhere in the brain and/or spine.\n* Patient must have either measurable or evaluable tumor as assessed by MRI of the brain and total spine\n* An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached to a ventricular access device or agreement to have one placed.\n* A minimum of 7 days between last dose of systemic chemotherapy and/or radiation therapy and first infusion of chemotherapy into fourth ventricle\n* Life expectancy of at least 12 weeks in the opinion of the principal investigator\n* Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater if > 16 years of age\n* Existing neurological deficits must have been stable for a minimum of 1 week prior to study enrollment\n* Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy\n* Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥ 500/µL, platelet count ≥ 50,000/µL (transfusion independent), and hemoglobin ≥ 9.0 gm/dL (may receive red blood cells(RBC) transfusions)\n* Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent.\n* Patient with prolonged QT interval on screening EKG will need cardiology consultation prior to enrollment\n* Patients with abnormal liver function tests (ALT, Aspartate Aminotransferase(AST),or total bilirubin) will need gastroenterology consultation prior to enrollment\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Enrolled in another treatment protocol\n* Has received another investigational or chemotherapy agent or radiation therapy within 7 days prior to intraventricular chemotherapy infusions\n* Evidence of untreated infection\n* Pregnant or lactating women",
    "miscellaneous_criteria": ""
}